Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 82 Published: October 31, 2021 Report Code: GMDGDHC2984TDB

The metabotropic glutamate receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline market research report provides comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key MoA in the metabotropic glutamate receptor 5 pipeline market?

The key MoA in the metabotropic glutamate receptor 5 pipeline market are Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 5 Agonist. Metabotropic Glutamate Receptor 5 Antagonist had the highest number of pipeline products in the metabotropic glutamate receptor 5 pipeline market.

Metabotropic glutamate receptor 5 pipeline market, by MoA

Metabotropic glutamate receptor 5 pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the metabotropic glutamate receptor 5 pipeline market?

The key RoA in the metabotropic glutamate receptor 5 pipeline market is oral.

What are the key molecule type in the metabotropic glutamate receptor 5 pipeline market?

The key molecule type in the metabotropic glutamate receptor 5 pipeline market are small molecule and peptide. Small molecule has the highest number of pipeline products in the metabotropic glutamate receptor 5 pipeline market.

Metabotropic glutamate receptor 5 pipeline market, by molecule type

Metabotropic glutamate receptor 5 pipeline market, by molecule type

For more molecule type insights, download a free report sample

What are the key companies in the metabotropic glutamate receptor 5 pipeline market?

Some of the key companies in the metabotropic glutamate receptor 5 pipeline market are Addex Therapeutics Ltd, Allos Pharma Inc, Allyx Therapeutics Inc, Bristol-Myers Squibb Co, Hua Medicine Shanghai Ltd, and Laboratorio Farmaceutico CT Srl.

Metabotropic glutamate receptor 5 pipeline market, by companies

Metabotropic glutamate receptor 5 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Key MoA Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 5 Agonist
Key RoA Oral
Key molecule type Small Molecule and Peptide
Key companies Addex Therapeutics Ltd, Allos Pharma Inc, Allyx Therapeutics Inc, Bristol-Myers Squibb Co, Hua Medicine Shanghai Ltd, and Laboratorio Farmaceutico CT Srl.

 

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
  • The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

Addex Therapeutics Ltd

Allos Pharma Inc

Allyx Therapeutics Inc

Bristol-Myers Squibb Co

Hua Medicine Shanghai Ltd

Laboratorio Farmaceutico CT Srl

Lactocore Inc

Noema Pharma AG

Novartis AG

Park Active Molecules

Richter Gedeon Nyrt

Tempero Bio

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Overview

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Allos Pharma Inc

Allyx Therapeutics Inc

Bristol-Myers Squibb Co

Hua Medicine Shanghai Ltd

Laboratorio Farmaceutico CT Srl

Lactocore Inc

Noema Pharma AG

Novartis AG

Park Active Molecules

Richter Gedeon Nyrt

Tempero Bio

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Drug Profiles

alloswitch-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-952048 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant IR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0014242 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCGM-10 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOE-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-12 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize mGluR5 for Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize MGLUR5 for Anxiety Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0431316 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467558 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Dormant Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Discontinued Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Product Development Milestones

Featured News & Press Releases

Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in blepharospasm

Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s Disease

May 17, 2021: Addex’s Dipraglurant restores synaptic plasticity in models of Dystonia

Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results

Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome

Dec 13, 2018: Sosei Heptares starts new clinical development program – First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders

Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF

11.5 per Share

Feb 06, 2017: Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases

Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Addex Therapeutics Ltd, 2021

Pipeline by Allos Pharma Inc, 2021

Pipeline by Allyx Therapeutics Inc, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Hua Medicine Shanghai Ltd, 2021

Pipeline by Laboratorio Farmaceutico CT Srl, 2021

Pipeline by Lactocore Inc, 2021

Pipeline by Noema Pharma AG, 2021

Pipeline by Novartis AG, 2021

Pipeline by Park Active Molecules, 2021

Pipeline by Richter Gedeon Nyrt, 2021

Pipeline by Tempero Bio, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Discontinued Products, 2021

Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.